Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
44 hedge funds and large institutions have $63.7M invested in Adamas Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
16% more funds holding
Funds holding: 38 → 44 (+6)
12% more capital invested
Capital invested by funds: $57M → $63.7M (+$6.71M)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.85M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$1.15M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.06M |
| 4 |
State Street
Boston,
Massachusetts
|
+$391K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$391K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$586K |
| 2 |
Jane Street
New York
|
-$545K |
| 3 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$514K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$486K |
| 5 |
D.E. Shaw & Co
New York
|
-$351K |
ADMS Hedge Fund Activity: Q3 2014 in Review
44 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2014, worth a combined $63.7M — up 12% from $57M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADMS positions and 4 closed out — a net gain of 6 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.85M. The largest seller was JP Morgan Chase, cutting an estimated $586K.
- 44 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2014, up from 38 in Q2 2014.
- Funds reported $63.7M of Adamas Pharmaceuticals stock for Q3 2014, up 12% quarter-over-quarter.
- 10 funds opened new Adamas Pharmaceuticals positions in Q3 2014 and 4 closed out, a net change of +6 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2014 was Fidelity Investments, an estimated $3.85M added.
- The largest Adamas Pharmaceuticals seller in Q3 2014 was JP Morgan Chase, an estimated $586K sold.
Based on aggregated 13F filings for Q3 2014.